ICON Q3 Bookings Hit Record as 2026 EPS Outlook Narrows

ICON plc reported record third-quarter net business wins and narrowed its full-year adjusted earnings outlook, as stronger bookings and a sequential improvement in profitability contrasted with lower year-over-year revenue and adjusted earnings.

For the quarter ended September 30, 2026, the clinical research services company generated revenue of $2.025 billion, down from $2.084 billion a year earlier and from $2.063 billion in the second quarter. Adjusted EBITDA was $336.9 million, compared with $387.7 million in the prior-year period, while the adjusted EBITDA margin fell to 16.6% from 18.6%.

Sequentially, however, the margin increased by 70 basis points from 15.9%. Adjusted diluted earnings per share rose 4% from the second quarter to $2.66, though it remained below the $3.20 reported in the third quarter of 2025. Adjusted net income was $205.8 million, versus $249.7 million a year earlier.

On a GAAP basis, ICON recorded net income of $122.1 million, or $1.58 per diluted share, compared with a net loss of $284.2 million, or $3.67 per share, in the year-earlier quarter. The 2025 period included $364.2 million of goodwill impairment and $101.0 million of impairment charges related to non-financial assets in the company’s Data Solutions reporting unit.

Record bookings support backlog

Net business wins reached a record $3.15 billion, reflecting gross awards of about $3.8 billion and cancellations of roughly $600 million. Quarterly net book-to-bill was 1.56 times, while trailing-12-month direct fee book-to-bill was 1.3 times.

ICON said demand remained positive and highlighted the expansion of enterprise partnerships across large pharmaceutical, mid-sized and biotechnology customers. The company also attributed differentiated booking performance to its AI-enabled digital platform, while identifying agentic, therapeutic and laboratory capabilities as areas of strategic investment.

Reported backlog increased 4.8% to $24.5 billion at September 30 from $23.4 billion at June 30. Unsatisfied performance obligations rose 4.6% to $16.4 billion from $15.7 billion. The presentation also identified awarded projects that had not yet been contracted and adjustments to the realizable value of contracted awards as part of its updated backlog policy.

ICON’s revenue base became modestly more diversified during the quarter. Its five largest customers accounted for 23.7% of revenue, down from 24.1% a year earlier, while customers outside the top 25 contributed 36.9%, up from 35.1%. The company said average revenue per customer was approximately 5% for its five largest customers, 3% for customers ranked sixth through 10th, and 1.6% for those ranked 11th through 25th.

Guidance range narrows

ICON updated its 2026 revenue guidance to between $8.10 billion and $8.20 billion, compared with its previous range of $7.85 billion to $8.15 billion. It now expects adjusted diluted EPS of $10.35 to $10.65, narrowing the prior range of $10.00 to $11.00.

The adjusted EPS outlook excludes amortization of intangible assets, stock-based compensation, foreign-exchange gains and losses, restructuring costs, transaction and integration expenses, certain financing costs, investment gains, impairments and related tax effects. ICON did not provide a reconciliation to GAAP guidance because it said some components could not be predicted with reasonable certainty without unreasonable effort.

Free cash flow totaled $302.4 million in the quarter, up from $243.6 million in the second quarter but below $333.9 million a year earlier. Cash from operating activities was $340.4 million, and capital expenditure was $38.0 million. Trailing-12-month free cash flow was $857.1 million.

ICON ended September with $809.0 million in cash and cash equivalents and $3.38 billion of total debt, resulting in net debt of $2.57 billion. Its net debt-to-trailing-12-month adjusted EBITDA ratio was 2.0 times, compared with 1.8 times at both June 30, 2026, and September 30, 2025. During the quarter, the company completed $400 million of share repurchases and a $2.15 billion debt refinancing.

The company cautioned that its outlook remains subject to pharmaceutical-industry demand, client concentration, project wins and execution, competition, strategic-partnership performance, foreign-exchange movements, inflation and labor costs. ICON also cited uncertainty surrounding the timing and effectiveness of efforts to remediate material weaknesses in its internal control over financial reporting.